SM
GBT

Sabby Management’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Sabby Management’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-254,029
Closed -$4.84M – 349
2016
Q2 		$4.21M Buy
254,029
+117,029
+85% +$2.36M 0.22% 62
2016
Q1 		$2.17M Sell
137,000
-205,857
-60% -$3.66M 0.11% 91
2015
Q4 		$6.45M Hold
342,857
– – 0.35% 49
2015
Q3 		$14.5M Buy
+342,857
New +$16.2M 0.6% 29

Other funds holding GBT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sabby Management's GBT Position: Q3 2016 in Review

Sabby Management sold out of Global Blood Therapeutics, Inc. (GBT) in Q3 2016, closing a stake of 254,029 shares — an estimated $4.84M sold.

Sabby Management first reported a position in GBT in Q3 2015 and held it in 4 quarters. The position peaked at $14.5M in Q3 2015. 84 funds tracked by Wall St. Rank hold GBT as of Q3 2016.

  • Sabby Management reported no remaining Global Blood Therapeutics, Inc. position as of Q3 2016 after selling out during the quarter.
  • Sabby Management sold 254,029 Global Blood Therapeutics, Inc. shares in Q3 2016, an estimated $4.84M.
  • Sabby Management first reported a position in Global Blood Therapeutics, Inc. in Q3 2015 and held it in 4 quarters.
  • Sabby Management's Global Blood Therapeutics, Inc. position peaked at $14.5M in Q3 2015.
  • 84 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q3 2016.

Based on Sabby Management's 13F filing for Q3 2016, filed 14 Nov 2016.